|Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|Outline of Final Research Achievements
The purpose is to realize cell therapies using human iPS cell-derived nephron progenitor cells (hiPSC-NPCs) for kidney diseases by developing efficient expansion culture methods for hiPSC-NPCs. We have developed expansion culture methods for hiPSC-NPCs more than 100-times and identified multiple low weight molecular compounds that increase hiPSC-NPCs by about 20-30%. Furthermore, we have identified the specific surface marker for nephron progenitor cells (NPCs) and succeeded in purifying the NPC fractions from multiple human iPS cell lines. We have improved renal function in a mouse model of acute kidney injury using expanded hiPSC-NPCs. In addition, we have improved renal function and suppressed the progression of renal fibrosis and aging in a mouse model of chronic kidney disease.